Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ONTX Onconova Therapeutics Inc

0.00 (0.00%)
Jun 13 2024 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 0
Bid Price 1.00
Ask Price 1.05
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Onconova Therapeutics Inc ONTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 0.9953 20:00:00
Open Price Low Price High Price Close Price Prev Close
0.9953 0.9953
Trades Volume Avg Volume 52 Week Range
0 0 - 0.5509 - 1.25
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.9953 USD

Onconova Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
21M 21.00M - 226k -18.95M -0.90 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Onconova Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No ONTX Message Board. Create One! See More Posts on ONTX Message Board See More Message Board Posts

Historical ONTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.8791.100.76550.9829934284,3460.116313.23%
6 Months0.77281.100.650.83707499,4450.222528.79%
1 Year1.091.250.55090.7876747132,811-0.0947-8.69%
3 Years7.157.830.55093.69364,969-6.15-86.08%
5 Years34.9040.000.55097.437,559,135-33.90-97.15%

Onconova Therapeutics Description

Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.

Your Recent History

Delayed Upgrade Clock